Vantage logo

First blood: Rubius approaches its big test

The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…

Vantage logo

Reneuron’s reinvention falters

More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.